32 completed, 3 not yet recruiting, 3 recruiting, 1 suspended. 34 Phase 1, 9 Phase 2, 2 Not applicable.
Follow Sanaria Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina Faso PfSPZ-LARC2 Vaccine, PfSPZ Challenge, Normal Saline - Malaria (Plasmodium Falciparum) | Phase 1 | Not yet recruiting | Sanaria Inc. | 45 | 2027-03-01 | 2026-07-31 |
| Malaria CVD 36000; Gates INV090205 PfSPZ Challenge (NF54), Wearable Biosensor Devices, Placebo - Malaria (Plasmodium Falciparum) | Phase 1 | Not yet recruiting | University of Maryland, Baltimore | 32 | 2026-11-01 | 2026-09-09 |
| PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali PfSPZ-LARC2 Vaccine, Normal Saline - Malaria (Plasmodium Falciparum) | Phase 2 | Recruiting | Sanaria Inc. | 300 | 2026-07-20 | 2026-07-23 |
| Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults Genetically attenuated PfSPZ Vaccine, Normal Saline (0.9% Sodium Chloride) - Malaria (Plasmodium Falciparum) | Phase 2 | Recruiting | Sanaria Inc. | 180 | 2026-05-04 | 2026-06-01 |
| Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults Normal Saline (Placebo), PfSPZ-LARC2 Vaccine, PfSPZ Challenge (NF54) - Malaria Falciparum | Phase 1 | Recruiting | Sanaria Inc. | 58 | 2026-03-12 | 2026-06-22 |
| Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults Pyronaridine Tetraphosphate, Artesunate Drug Combination, PfSPZ Challenge (NF54), MVA ME-TRAP - Malaria | Phase 1 / Phase 2 | Not yet recruiting | University Hospital Tuebingen | 30 | 2025-06-01 | 2024-12-06 |
| Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso PfSPZ-LARC2 Vaccine, Normal Saline (Placebo) - Malaria Falciparum, Malaria Infection | Phase 1 | Completed | Sanaria Inc. | 75 | 2025-03-04 | 2026-04-16 |
| A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI PfSPZ Vaccine, PfSPZ Challenge (7G8), Normal Saline - Malaria, Malaria,Falciparum | Phase 1 | Terminated | Sanaria Inc. | 31 | 2022-12-06 | 2024-11-25 |
| Controlled Human Malaria Infection Transmission Model - Phase A PfSPZ Challenge, Sulfadoxine-Pyrimethamine, Piperaquine - Malaria,Falciparum | Phase 1 / Phase 2 | Suspended | University of Oxford | 44 | 2022-08-22 | 2024-05-23 |
| Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria PfSPZ Vaccine, PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis, Normal Saline - Malaria | Phase 2 | Completed | Sanaria Inc. | 345 | 2022-05-07 | 2026-05-04 |
| PfSPZ Vaccine Trial in Malian Children Sanaria® PfSPZ Vaccine, Normal Saline - Malaria, Malaria,Falciparum | Phase 2 | Completed | Sanaria Inc. | 290 | 2022-04-01 | 2024-02-07 |
| Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults PfSPZ Vaccine, PfSPZ Challenge (7G8) for CHMI, Normal Saline - Malaria | Phase 1 | Completed | Sanaria Inc. | 54 | 2021-09-27 | 2022-07-18 |
| Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet, PfSPZ-DVI Challenge - Malaria,Falciparum, Parasitemia | Phase 1 | Completed | Medicines for Malaria Venture | 16 | 2020-02-19 | 2021-09-05 |
| Safety, Tolerability and Chemoprotective Activity of P218 in PfSPZ Challenge Model P218 (1000 mg) Oral Capsules, Placebo Oral Capsules, P218 (100 mg) Oral Capsules - Malaria | Phase 1 | Completed | Medicines for Malaria Venture | 32 | 2018-11-16 | 2021-04-09 |
| Regimen Optimization Trial of PfSPZ Vaccine in Equatorial Guinea PfSPZ Vaccine, Normal saline, PfSPZ Challenge (for CHMI) - Malaria | Phase 1 | Completed | Sanaria Inc. | 104 | 2018-07-30 | 2020-01-07 |
| Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in Gabonese Children PfSPZ Vaccine, Normal Saline - Malaria | Phase 2 | Completed | Sanaria Inc. | 200 | 2018-06-14 | 2021-10-07 |
| Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali PfSPZ Vaccine, Normal Saline, artemether 20mg/lumefantrine 120mg (AL) - Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 478 | 2018-05-14 | 2021-08-20 |
| Susceptibility of Gambian Adults to PfSPZ-Challenge Infection in the Controlled Human Malaria Infection Model PfSPZ Challenge - Malaria | Not applicable | Completed | London School of Hygiene and Tropical Medicine | 19 | 2018-03-29 | 2019-01-16 |
| Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian Adults PfSPZ Vaccine, Normal Saline Placebo, PfSPZ Challenge - Malaria, Malaria,Falciparum | Phase 1 | Completed | Sanaria Inc. | 21 | 2018-02-07 | 2019-04-05 |
| Chemoprotective Activity of MMV390048 in PfSPZ Challenge Model MMV390048 - Malaria,Falciparum | Phase 1 | Withdrawn | Medicines for Malaria Venture | 2018-01-01 | 2018-02-05 |
Showing 20 of 42. Sign in to see all of them.
Malaria (38) · Malaria, Falciparum (35) · Parasitemia (2) · Parasitic Diseases (2) · Protozoan Infections (2) · Infections (1) · Sickle Cell Trait (1)
Saline Solution (20) · Sodium Chloride (4) · Artemether, Lumefantrine Drug Combination (3) · 1-acetyl-1,2,3,3a,8,8a-hexahydro-8a-hydroxy-5-methoxypyrrolo(2,3-b)indole (1) · Artemether (1) · Atovaquone (1) · Chemoprevention (1) · Lumefantrine (1) · MMV390048 (1) · Primaquine (1) · Proguanil (1) · Pyrimethamine (1) · Vaccines (1) · atovaquone, proguanil drug combination (1) · chloroquine diphosphate (1)
United States (7) · Germany (5) · Mali (4) · Tanzania (4) · Burkina Faso (3) · Equatorial Guinea (3) · Kenya (3) · Netherlands (3) · Belgium (2) · Gabon (2) · Indonesia (1) · Spain (1) · The Gambia (1) · United Kingdom (1)
Salim Abdulla, MD, PhD (3) · Patrick E Duffy, M.D. (2) · Said Jongo, MD, MMED (2) · Sodiomon B Sirima, MD PhD (2) · Adrian VS Hill, DPhil FRCP (1) · Alassane Dicko, MD PhD (1) · Alexandra Singer, MD (1) · Bertrand Lell, MD (1) · Cristina Donini, PhD (1) · Erni J Nelwan, MD, Ph.D. (1) · Farouk Chughlay, MD (1) · Issaka Sagara, MD MSPH PhD (1)
PMID 41014333, PMID 21903775, PMID 23149582, PMID 23823332, PMID 25070995, PMID 25889522, PMID 26169270, PMID 26245196, PMID 27790201, PMID 28031267, PMID 28097230, PMID 28199305, PMID 28216244, PMID 29141739, PMID 29438525, PMID 29943719, PMID 31036014, PMID 31402382, PMID 31555824, PMID 31782768, PMID 31803847, PMID 32444192, PMID 32920641, PMID 34194041, PMID 34264864, PMID 34518679, PMID 35073864, PMID 35331251, PMID 35835738, PMID 35999221, PMID 37160281, PMID 37309249, PMID 37310872, PMID 37384799, PMID 38194272, PMID 38716733, PMID 39153490, PMID 40098097, PMID 40972633, PMID 41176969, PMID 42086568
2015 (1), 2016 (1), 2017 (1), 2018 (1), 2019 (1), U44AI167783 (1)